Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (McMaster University)
- Development stage
- Unknown
- Lead developer
- McMaster University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal, Oral
01
Overview
Fresh fecal microbiota transplantation (FMT) is a microbial therapy involving the transfer of minimally processed stool from a healthy donor to a patient, typically within 6 to 24 hours of collection. The primary mechanism of action is the restoration of a diverse and functional intestinal microbiome, which provides colonization resistance against pathogens like *Clostridioides difficile*. By reintroducing a complex community of commensal bacteria, fungi, and viruses, FMT outcompetes *C. difficile* for nutrients and niche space, and restores bile acid metabolism, which inhibits *C. difficile* germination and growth. Fresh FMT is often compared to frozen-and-thawed preparations in clinical trials to evaluate whether the lack of cryopreservation offers superior efficacy or safety in treating recurrent infections.
- Other names
- Fresh FMTallogeneic fecal microbiotafecal microbiota transplant
02
Targets
Gut microbiota
Beyond the preview
Go deeper on fecal microbiota transplantation (McMaster University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (McMaster University).